Christopher S. Ambrose

Author

Also Known As

Ambrose CS, C Ambrose, C S Ambrose, C. Ambrose, C. S. Ambrose, C.S. Ambrose, CHRISTOPHER AMBROSE, Chris Ambrose, Christopher Ambrose, Christopher S Ambrose

289

Publications

6.1K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United States)Amgen (United States)Wake Forest University University of Colorado Denver Altimmune (United States)

About

Christopher S. Ambrose is an author at AstraZeneca (United States) specializing in medicine, influenza vaccines, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	985
2	Public Health	11	12	397
3	Health Sciences	1	1	15
4	Natural Sciences	1	1	100
5	Allergy	1	1	15

Christopher S. Ambrose

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials Gaston De Serres, Danuta M. Skowronski, Xionghua Wu, Eurosurveillance	2013	254
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials Jonathan Corren, Andrew Menzies‐Gow, Geoffrey Chupp, American Journal of Respiratory and Critical Care Medicine	2023	142
Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity Robert B. Belshe, Kathleen Coelingh, Christopher S. Ambrose, Vaccine VaccinationAntigenic SimilarityVaccine DevelopmentVaccine TargetImmunology	2009	140
The role of nasal IgA in children vaccinated with live attenuated influenza vaccine Christopher S. Ambrose, Xionghua Wu, Taff Jones, Vaccine	2012	113
Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age Robert B. Belshe, Christopher S. Ambrose, Tingting Yi Vaccine VaccinationVaccine SafetyVaccinologyVaccine TestingPediatrics	2008	106
Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age Stan L. Block, Ram Yogev, Frederick G. Hayden, Vaccine VaccinologyVaccine SafetyVaccinationInfluenza Vaccine VirusVaccine Development	2008	106
A novel G protein-coupled receptor kinase gene cloned from 4p16.3 Christopher S. Ambrose, Molly F. James, Glenn Barnes, Human Molecular Genetics GeneticsGenomic MechanismMolecular BiologyMolecular GeneticsDisease Gene Identification	1992	100
Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis Christopher S. Ambrose, Evan J. Anderson, Eric A. F. Simões, The Pediatric Infectious Disease Journal	2013	88
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial PK Judge, Natalie Staplin, KJ Mayne, The Lancet Diabetes & Endocrinology	2023	88
Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012 Susan T. Pastula, Judith Hackett, Jenna E. Coalson, Open Forum Infectious Diseases	2017	87

Page 1